TY - JOUR
T1 - Retinopathy of prematurity in the United Kingdom
T2 - retreatment rates, visual and structural 1-year outcomes
AU - UK Retinopathy of Prematurity Special Interest Group
AU - Adams, Gillian Gw
AU - Bunce, Catey
AU - Xing, Wen
AU - Butler, Lucilla
AU - Long, Vernon
AU - Reddy, Aravind
AU - Dahlmann-Noor, Annegret H.
AU - Abbott, Joseph
AU - Aclimandos, Wagih
AU - Adams, Gill
AU - Al-Khaier, Ayman
AU - Allen, Louise
AU - Arashvan, Kayvan
AU - Ashworth, Jane
AU - Barampouti, Faye
AU - Barnes, Jonathan
AU - Barrett, Victoria
AU - Barry, John Sebastian
AU - Bates, Adam
AU - Berk, Tulin
AU - Biswas, Susmito
AU - Blaikie, Andrew
AU - Brennan, Rosie
AU - Bunting, Howard
AU - Butcher, Jeremy
AU - Chan-Ling, Tailoi
AU - Chan, Jonathan
AU - Child, Christopher
AU - Choi, Jessy
AU - Clark, David
AU - Clifford, Luke
AU - Dabbagh, Ahmad
AU - Dahlmann-Noor, Annegret
AU - Dawidek, Gervase
AU - Dhir, Luna
AU - Drake, Karen
AU - Edwards, Richard
AU - Esakowitz, Leonard
AU - Escardo-Paton, Julia
AU - Evans, Anthony
AU - Fleck, Brian
AU - Geh, Vernon
AU - George, Nick
AU - Gnanaray, Lawrence
AU - Goyal, Raina
AU - Haigh, Paul
AU - Hancox, Joanne
AU - Haynes, Richard
AU - Jones, David
AU - Taylor, Robert
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Aims: To evaluate retreatment rates, visual and anatomical outcomes at 1-year postnatal age in infants treated for retinopathy of prematurity (ROP) Methods: Longitudinal national surveillance study of infants treated for ROP in the United Kingdom between December 2013 and December 2014, supported by the British Ophthalmic Surveillance Unit. Here we report retreatment rates, anatomical, visual and refractive outcomes at 1-year follow-up. Results: One-year follow-up forms were completed for 168 children of the original cohort of 327 (51.4%). Twenty-two had at least one retreatment: 17/153 right eyes (REs, 11.1%) after initial diode laser, and 5/14 REs (35.7%) after initial injection of anti-vascular endothelial growth factor (VEGF) antibody. Median (interquartile range) RE best-corrected visual acuity was 0.6 (0.4–1.0) (n = 46 REs), and median acuity both eyes open 0.4 (0.3–0.7) logMAR (n = 89). Median spherical equivalent (RE) was 0.44 (−1.3 to 1.3) dioptre (D) (n = 116). Median astigmatism (RE) was 0.5 (0–1.0) D (n = 111), and median anisometropia 0.125 (0–0.75) D (n = 116). Twenty-four children (20.5%) had been prescribed glasses. Sight impairment certification eligibility information was available for 131 children: 11 (8.4%) were eligible to be certified as sight impaired, and 5 (3.8%) as severely sight impaired. Conclusions: Retreatment rates are in line with previous reports, and appear higher after initial anti-VEGF antibody than after initial diode laser. Refractive outcomes are in line with previous studies, with a trend towards early emmetropia and myopia following diode laser, particularly in more severe ROP.
AB - Aims: To evaluate retreatment rates, visual and anatomical outcomes at 1-year postnatal age in infants treated for retinopathy of prematurity (ROP) Methods: Longitudinal national surveillance study of infants treated for ROP in the United Kingdom between December 2013 and December 2014, supported by the British Ophthalmic Surveillance Unit. Here we report retreatment rates, anatomical, visual and refractive outcomes at 1-year follow-up. Results: One-year follow-up forms were completed for 168 children of the original cohort of 327 (51.4%). Twenty-two had at least one retreatment: 17/153 right eyes (REs, 11.1%) after initial diode laser, and 5/14 REs (35.7%) after initial injection of anti-vascular endothelial growth factor (VEGF) antibody. Median (interquartile range) RE best-corrected visual acuity was 0.6 (0.4–1.0) (n = 46 REs), and median acuity both eyes open 0.4 (0.3–0.7) logMAR (n = 89). Median spherical equivalent (RE) was 0.44 (−1.3 to 1.3) dioptre (D) (n = 116). Median astigmatism (RE) was 0.5 (0–1.0) D (n = 111), and median anisometropia 0.125 (0–0.75) D (n = 116). Twenty-four children (20.5%) had been prescribed glasses. Sight impairment certification eligibility information was available for 131 children: 11 (8.4%) were eligible to be certified as sight impaired, and 5 (3.8%) as severely sight impaired. Conclusions: Retreatment rates are in line with previous reports, and appear higher after initial anti-VEGF antibody than after initial diode laser. Refractive outcomes are in line with previous studies, with a trend towards early emmetropia and myopia following diode laser, particularly in more severe ROP.
UR - http://www.scopus.com/inward/record.url?scp=85049946782&partnerID=8YFLogxK
U2 - 10.1038/s41433-018-0151-y
DO - 10.1038/s41433-018-0151-y
M3 - Article
C2 - 30013158
AN - SCOPUS:85049946782
SN - 0950-222X
VL - 32
SP - 1752
EP - 1759
JO - Eye (Basingstoke)
JF - Eye (Basingstoke)
IS - 11
ER -